Bruker, maker of high-performance scientific instruments, is expanding its CRO business through a majority ownership deal with Switzerland-based Biognosys, which produces proteomics solutions for R&D and clinical trials.
Under terms of the deal, Biognosys co-founder and CEO Oliver Rinner and other members of the company’s leadership team will remain on board to manage Biognosys, which is known for its proteomics and proteogenomics CRO services and proteomics software.
Financial terms of the deal weren’t disclosed. J.P. Morgan served as financial adviser to Biognosys, and several of the company’s early investors sold their shares to Bruker in a secondary transaction, the company said in a Jan. 4 press release. Bruker will now make new primary investments in Biognosys.
Biognosys also said it plans to open an advanced proteomics CRO services laboratory in the U.S.
“We are delighted to partner with Biognosys to expand our CRO business in the U.S.,” Rohan Thakur, president of the Bruker life science mass spectrometry division, said in the release. “With the rapid scientific acceptance of dia-PASEF workflows, our partnership offers a unique combination of proteomics applications and data-science expertise, which can benefit more biopharma and diagnostics companies in using unbiased proteomics for decision-making.”
Dia-PASEF technology uses ion mobility separation to reduce signal interferences and increase sensitivity in proteomic experiments.
The Bruker-Biognosys combo will link Biognosys’ portfolio of proprietary proteomics services, software and kits with Bruker’s 4D proteomics timsTOF technology.